"The global clinical trials market is estimated to grow at a CAGR of 5.7% between USD 47.5 billion in 2022 and USD 78.3 billion by 2031. Throughout the forecast period, North America is expected to dominate the market."
Advances in clinical trial technology, a growing need for innovative therapies, and an increase in the prevalence of chronic illnesses are all driving a significant expansion in the clinical study industry. Rising R&D investments by pharmaceutical companies, a greater emphasis on personalised therapy, and favourable legislative laws are all factors propelling market expansion even further. Nonetheless, rigorous rules, patient recruitment issues, and high costs may impede progress.
Market Trend Acceptance of virtual and distributed clinical trials
Offering improved patient involvement and data collecting efficiency, the move towards distributed and virtual clinical trials is transforming the sector. The COVID-19 epidemic has sped this tendency as it required remote trial operations. Using digital technologies such wearable devices, telemedicine, and electronic patient-reported outcomes (ePRO), decentralized trials help to allow remote patient monitoring and data collecting.
This strategy lowers geographic obstacles and increases convenience, hence improving patient recruitment and retention. It also makes real-world data collecting possible and lets more varied patient groups exist. Decentralized trials are projected to proliferate as technology develops and regulatory authorities embrace new models, therefore transforming the field of clinical research.
Increasing frequency of chronic illnesses and need for creative treatments
The desire for fresh and efficient therapies resulting from the increasing worldwide load of chronic illnesses is pushing development in the clinical trials industry. Aging populations, inactive lifestyles, and environmental elements are driving the frequency of chronic illnesses like cancer, cardiovascular disorders, and diabetes. This has made creative ideas and individualized treatment plans rather necessary. Higher numbers of clinical trials are the outcome of pharmaceutical and biotechnology businesses actively spending in research and development to meet these unmet medical requirements.
Furthermore widening the range of clinical research is the emphasis on uncommon illnesses and orphan medication development. The market for clinical trials is predicted to develop steadily as the healthcare sector works to offset the increasing illness load.
High expenses and challenging nature of clinical research
Market development is seriously hampered by rising expenses and growing complexity of clinical studies. Clinical research calls for large expenditures in infrastructure, technology, staff, and regulatory compliance. Including clinical trial costs, the average cost of launching a new medicine into the market has been calculated to be more than $2 billion. Tight regulations, sophisticated trial designs, and the need of specialist knowledge are among the elements driving growing expenses.
Further increasing expenses include the rising emphasis on rare illnesses and customized therapy, which often calls for more complex trial designs and smaller patient groups. Smaller biotech firms and academic institutions especially find the financial load of clinical studies to be very difficult, therefore maybe restricting attempts at innovation and medication development. Stakeholders are looking at affordable solutions such risk-based monitoring, adaptive trial designs, and using real-world data to help to alleviate this constraint.
Phase III takes front stage in the market.
Crucially in proving the safety and effectiveness of novel medicines in large patient groups are phase III studies. Usually including hundreds of people, these studies are carried out at many locations—often abroad. Phase III studies' complexity and scope demand large expenditures in data administration, regulatory compliance, and patient recruiting.
Furthermore important for getting regulatory clearance and deciding if novel medications are commercially viable are the results of Phase III studies. The need for well-designed and well carried out Phase III studies is still strong as pharmaceutical firms keep concentrating on introducing new treatments to market, which drives the predominance of this category in the clinical trials market.
Leading the clinical trials industry is North America, which dominates because of its sophisticated healthcare system and large R&D spending.
Particularly the United States, North America occupies the biggest proportion in the worldwide clinical trials market. Major pharmaceutical and biotechnology firms, reputable research institutes, and a friendly regulatory environment help to explain this dominance in numerous respects. The area benefits from significant healthcare R&D spending; the United States leads constantly in terms of new medicine approvals and clinical trial starts. Modern medical facilities and technological platforms included in advanced healthcare infrastructure help to enable effective trial operations. Furthermore, North America's strong focus on innovation and tailored treatment stimulates the need for clinical research in many different therapeutic domains. The area gains from a great pool of seasoned researchers and clinical study experts as well. North America is likely to maintain its dominant role in the clinical trials market throughout the projection period, while other areas are fast developing.
The clinical trials market is highly competitive and fragmented, with rivals ranging from multinational pharmaceutical companies to specialist contract research organisations (CROs). Key market companies are constantly seeking to improve their goods and expand their geographical reach through strategic partnerships, mergers, and acquisitions. Major pharmaceutical companies occasionally conduct in-house clinical trials while outsourcing to CROs to capitalise on specialised knowledge and increase cost efficiency. To speed up trials and improve data quality, CROs are increasingly turning to technology-driven solutions.
Speciality firms that focus on specific therapeutic domains or trial stages are also growing in the industry. Companies with strong expertise in patient recruitment, data analytics, and regulatory compliance will likely gain a competitive advantage as demand for complex and global clinical research develops.
1. IQVIA
2. Parexel International Corporation
3. Pharmaceutical Product Development, LLC (PPD)
4. Charles River Laboratories
5. ICON plc
6. Syneos Health
7. Medpace
8. Wuxi AppTec
9. PRA Health Sciences
10. Chiltern International Ltd.
11. SGS SA
12. Clinipace
IQVIA debuted an AI-powered clinical trial optimization tool in 2023 to improve patient recruitment and trial design effectiveness.
To increase its digital capabilities in clinical research, Parexel International Corporation bought Calyx, a medical imaging and clinical trial technology firm, in 2022.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Clinical Trials Market (2018 – 2022)
3.2. Global Clinical Trials Market (2023 – 2031)
3.2.1. Market Segment By Phase (2023 – 2031)
3.2.2. Market Segment By Study Design (2023 – 2031)
3.2.3. Market Segment By Indication (2023 – 2031)
3.2.4. Market Segment By End User (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Adoption of decentralized and virtual clinical trials
4.1.2. Increasing use of artificial intelligence in clinical trials
4.1.3. Rise of patient-centric trial designs
4.2. Market Drivers
4.2.1. Growing prevalence of chronic diseases and demand for innovative therapies
4.2.2. Increasing R&D investments by pharmaceutical and biotechnology companies
4.2.3. Advancements in clinical trial technologies
4.3. Market Restraints
4.3.1. High costs and complexity of clinical trials
4.3.2. Patient recruitment and retention challenges
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY PHASE (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Phase I
5.2. Phase II
5.3. Phase III
5.4. Phase IV
6. BY STUDY DESIGN
6.1. Interventional
6.2. Observational
6.3. Expanded Access
7. BY INDICATION
7.1. Oncology
7.2. Cardiovascular
7.3. Infectious Diseases
7.4. Others
8. BY END USER
8.1. Pharmaceutical & Biotechnology Companies
8.2. Contract Research Organizations
8.3. Academic & Research Institutes
9. GEOGRAPHY
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. South America
9.2.1. Brazil
9.2.2. Argentina
9.2.3. Rest of South America
9.3. Europe
9.3.1. Germany
9.3.2. United Kingdom
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle-East
9.5.1. UAE
9.5.2. Saudi Arabia
9.5.3. Turkey
9.5.4. Rest of Middle East
9.6. Africa
9.6.1. South Africa
9.6.2. Egypt
9.6.3. Rest of Africa
10. COMPETITIVE LANDSCAPE
10.1. Key Developments
10.2. Company Market Share Analysis
10.3. Product Benchmarking
11. SWOT ANALYSIS
12. COMPANY PROFILES
12.1. IQVIA
12.2. Parexel International Corporation
12.3. Pharmaceutical Product Development, LLC (PPD)
12.4. Charles River Laboratories
12.5. ICON plc
12.6. Syneos Health
12.7. Medpace
12.8. Wuxi AppTec
12.9. PRA Health Sciences
12.10. Chiltern International Ltd.
12.11. SGS SA
12.12. Clinipace (*LIST NOT EXHAUSTIVE)
13. MARKET OPPORTUNITIES
By Phase:
- Phase I
- Phase II
- Phase III
- Phase IV
By Study Design:
- Interventional
- Observational
- Expanded Access
By Indication:
- Oncology
- Cardiovascular
- Infectious Diseases
- Others
By End User:
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Academic & Research Institutes
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
